Antigen-Detection in the Diagnosis of SARS-CoV-2 Infection Using Rapid Immunoassays [open pdf - 396KB]
From the Background: "Since the beginning of the COVID-19 [coronavirus disease 2019] pandemic, laboratories have been using nucleic acid amplification tests (NAATs), such as real time reverse transcription polymerase chain reaction (rRT-PCR) assays, to detect SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], the virus that causes the disease. In many countries, access to this form of testing has been challenging. The search is on to develop reliable but less expensive and faster diagnostic tests that detect antigens specific for SARS-CoV-2 infection. Antigen-detection diagnostic tests are designed to directly detect SARS-CoV-2 proteins produced by replicating virus in respiratory secretions and have been developed as both laboratory-based tests, and for near-patient use, so-called rapid diagnostic tests, or RDTs. The diagnostic development landscape is dynamic, with nearly a hundred companies developing or manufacturing rapid tests for SARS-CoV-2 antigen detection. This document offers advice on the potential role of antigen-detecting RDTs (Ag-RDT) in the diagnosis of COVID-19 and the need for careful test selection."
2020 World Health Organization. Posted here with permission. Document is under a Creative Commons license and requires proper attribution and noncommercial use to be shared: [https://creativecommons.org/licenses/by-nc-sa/3.0/igo/]
World Health Organization: https://www.who.int/